

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ILOODA CO., LTD. and JEISYS MEDICAL INC.,
Petitioners

v.

SERENDIA, LLC,
Patent Owner

U.S. PATENT NO. 9,775,774

Case No. IPR2024-00383

**JOINT MOTION TO TERMINATE ILOODA'S
PARTICIPATION IN THE PROCEEDING
AND
JOINT REQUEST TO KEEP THE SETTLEMENT AGREEMENT
SEPARATE AND CONFIDENTIAL AND ACCESSIBLE
ONLY TO THE BOARD, ILOODA, AND SERENDIA**

Pursuant to 35 U.S.C. § 317, 37 C.F.R. §§ 42.72 and 42.74, and the Board’s authorization by email dated April 3, 2024, Petitioner Ilooda Co., Ltd. (“Ilooda”) and Patent Owner Serendia, LLC (“Serendia”) jointly move to terminate the present *inter partes* review proceeding with respect to Ilooda in light of the settlement of their dispute regarding U.S. Patent No. 9,775,774 (“the ’774 patent”); and jointly request to keep the copy of the settlement agreement filed along with this paper (Confidential Exhibit 1026) separate and confidential and accessible only to the Board, Ilooda, and Serendia.

The parties have filed a true and complete copy of the settlement agreement along with this paper, as required by 35 U.S.C. § 317(b). *See* Confidential Exhibit 1026. The moving parties certify that there are no other agreements or understandings between them, including any collateral agreements, made in connection with, or in contemplation of, the termination of this proceeding with respect to Ilooda.

I. PROCEDURAL BACKGROUND

The Petition in this proceeding was filed on January 9, 2024 by Petitioners Ilooda and Jeisys. The Patent Owner’s preliminary response is due on April 23, 2024. *See* Paper No. 4. The Board has not yet issued a decision on institution.

On February 28, 2024, Ilooda and Serendia entered into a settlement agreement that resolves the dispute between Petitioner Ilooda and non-party Cutera,

Inc. (“Cutera”) and Patent Owner Serendia regarding the ’774 patent. *See* Confidential Exhibit 1026. On April 1, 2024, Ilooda, Cutera, and Serendia filed a joint motion to terminate the ITC investigation (*Certain Dermatological Treatment Devices and Components Thereof*, Inv. No. 337-TA-1356) as to Respondents Ilooda and Cutera based on settlement and requested the Administrative Law Judge limit service of the settlement agreement to Serendia, Ilooda, and the Commission Investigative Staff. The motion has not been granted yet.

The parties contacted the Board on April 3, 2024 by email, to request authorization to file a joint motion to terminate and joint request to keep the copy of the settlement agreement filed as Confidential Exhibit 1026 separate and confidential and accessible only to the Board, Ilooda, and Serendia. The Board authorized these filings in a responsive email on April 3, 2024.

The parties note that Petitioner Jeisys is not a party to the settlement agreement. Therefore, the parties are not requesting termination of the proceeding as to Jeisys. Additionally, the settlement agreement is being filed as “Only to Board” so that Jeisys does not have access to it.

II. GOOD CAUSE EXISTS TO TERMINATE THE ABOVE-CAPTIONED IPR AS TO PETITIONER ILOODA

First, Petitioner Ilooda and Patent Owner Serendia jointly request that this *inter partes* review be terminated with respect to Ilooda, in light of the settlement of

their dispute regarding the '774 patent.

Under 35 U.S.C. § 317(a), “[a]n *inter partes* review instituted under this chapter shall be terminated with respect to any petitioner upon the joint request of the petitioner and the patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed.” Additionally, as the Board has explained:

There are strong public policy reasons to favor settlement between the parties to a proceeding. . . . The Board expects that a proceeding will terminate after the filing of a settlement agreement, unless the Board has already decided the merits of the proceeding. 35 U.S.C. §§ 317(a), 327.

Consolidated Trial Practice Guide (November 2019), page 86 § II.N.

Termination of the present *inter partes* review with respect to Ilooda is appropriate because the moving parties have settled their entire dispute regarding the '774 patent and the Office has not yet decided the merits of the proceeding. Other factors weigh in favor of terminating this IPR proceeding as to Ilooda. First, the above-captioned petition is in its early phase, and the Board has not yet made a decision regarding institution of the petition, and no decisions on the merits of the proceeding have been made. Dismissal of the proceedings at this early stage promotes the Congressional goal to establish a more efficient and streamlined patent system that limits unnecessary and counterproductive litigation costs. *See* 37 C.F.R. § 42.1(b).

The Board regularly grants motions to terminate under similar circumstances. *See, e.g. RPC Formatec GMBH v. Trudell Medical Int'l*, Case Nos. IPR2014-01040, IPR2014-01127, Paper 10 (Oct. 24, 2014) (granting joint motion to terminate); *Samsung Electronics Co., Ltd. v. Telefonaktiebolaget LM Ericsson*, IPR2021-00446, Paper 7 (PTAB, Aug. 3, 2021) (same); *Huawei Technologies Co., Ltd. v. Verizon Patent and Licensing Inc.*, IPR2021-00616, -00617, Paper 9 (PTAB, Sept. 9, 2021) (same).

Further, termination of the proceeding as to Ilooda is a just and fair resolution. Ilooda and Serendia agree that neither Ilooda and Serendia will be prejudiced by the termination. Moreover, the remaining Petitioner, Jeisys, has confirmed that it does not object to the termination of this proceeding as to Ilooda. Finally, Ilooda and Serendia will benefit from preserving resources that would otherwise be expended if this motion is denied.

Therefore, Petitioner Ilooda and Patent Owner Serendia respectfully submit this *inter partes* review should be terminated with respect to Ilooda.

III. JOINT REQUEST TO TREAT SETTLEMENT AGREEMENT AS BUSINESS CONFIDENTIAL INFORMATION

Petitioner Ilooda and Patent Owner Serendia jointly request that the settlement agreement filed as Confidential Exhibit 1026 (a) be treated as business confidential information; (b) be kept separate from the file of the involved patent; (c) be accessible only to the Board, Ilooda, and Serendia, and not accessible to

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.